Agenus/$AGEN
1D1W1MYTD1Y5YMAX
Capital at risk
About Agenus
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.
- Ticker
- $AGEN
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 81
- Headquarters
- Lexington, United States
- Website
- www.agenusbio.com
Agenus Metrics
BasicAdvanced
$384M
3.41
$2.51
1.40
-
Price and volume
Market cap
$384M
Beta
1.4
52-week high
$8.85
52-week low
$2.71
Average daily volume
1M
Financial strength
Current ratio
0.34
Quick ratio
0.319
Long term debt to equity
-0.046
Total debt to equity
-0.198
Interest coverage (TTM)
0.60%
Profitability
EBITDA (TTM)
40.61
Gross margin (TTM)
113.61%
Net profit margin (TTM)
69.34%
Operating margin (TTM)
27.04%
Revenue per employee (TTM)
$1,640,000
Management effectiveness
Return on assets (TTM)
12.53%
Return on equity (TTM)
-33.92%
Valuation
Price to earnings (TTM)
3.408
Price to revenue (TTM)
2.343
Price to book
-1.83
Price to tangible book (TTM)
-1.61
Price to free cash flow (TTM)
-3.156
Free cash flow yield (TTM)
-31.68%
Free cash flow per share (TTM)
-2.706
Growth
Revenue change (TTM)
30.47%
Earnings per share change (TTM)
-136.68%
3-year revenue growth (CAGR)
10.13%
10-year revenue growth (CAGR)
17.24%
3-year earnings per share growth (CAGR)
-46.92%
10-year earnings per share growth (CAGR)
-19.05%
What the Analysts think about Agenus
Analyst ratings (Buy, Hold, Sell) for Agenus stock.
Analyst projections of the future price of Agenus stock.
Bulls say / Bears say
The peer-reviewed NEST Phase 2 update found a 59% pathological response rate in 22 MSS tumours, including a 32% complete response rate, with no recurrences reported at the data cut-off. This supports Agenus’s decision to move BOT+BAL into a curative-intent, pre-surgery setting, although ROBBIN must confirm the result in a randomised trial. (BioSpace)
In a 123-patient Phase 1b cohort of heavily pre-treated MSS metastatic colorectal cancer without active liver metastases, BOT+BAL produced median overall survival of 21.2 months and a 33% three-year survival rate. The durability is encouraging in a disease where conventional checkpoint immunotherapy has historically delivered limited benefit. (BioSpace)
Agenus has secured an FDA-aligned design for the planned 850-patient ROBBIN Phase 3 trial and raised an oversubscribed $85 million upfront, with up to $255 million more tied to trial milestones. That gives the lead programme a clearer registration path and more near-term funding support than it had before the financing. (Agenus, Agenus)
Despite the July financing, Agenus says its cash and net proceeds should fund operations only into the third quarter of 2027 if the warrants are not exercised. Its filing also says substantial doubt remains about its ability to continue as a going concern and that further capital will be needed to complete development and reach profitability. (StockTitan)
The July financing creates substantial potential dilution: the related filings cover about 23 million new common shares and up to roughly 55 million shares from purchase warrants, against about 45 million shares outstanding at the end of July. Investors therefore face significant dilution even if the trial progresses well. (StockTitan)
Agenus stopped future funding for the BATTMAN Phase 3 study, which was then terminated, and is concentrating resources on ROBBIN. That leaves the company more dependent on a single planned registrational trial whose first patient is not expected until the first quarter of 2027 and whose efficacy remains unproven in a randomised study. (BioSpace, StockAnalysis)
Data summarised monthly by Lightyear AI. Last updated on 23 Sept 2026.
Agenus Financial Performance
Revenues and expenses
Agenus Earnings Performance
Company profitability
Upcoming events
No upcoming events
Agenus News
AllArticlesVideos
Agenus to Present Three-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026
Business Wire2 weeks ago
Agenus to Participate in Upcoming September Investor Conferences
Business Wire4 weeks ago
Agenus Announces Peer-Reviewed Publication Linking BOT+BAL's Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism
Business Wire4 weeks ago
Funds containing Agenus
Fund name | Fund size | $AGEN weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.